Investigational Drug Study for Adults with IPF

Trial Objective

Investigational Drug Study for Adults with IPFThe purpose of this Galapagos N.V. sponsored research study is to determine if adding an investigational medication called GLPG1690 to existing therapy is safe and effective in treating patients with idiopathic pulmonary fibrosis. Patients will be asked to complete questionnaires, as well as perform spirometry tests, six-minute walk and other study tests during visits.

Enrollment

New enrollment for this trial is temporarily paused

Who Can Participate

Patients diagnosed with IPF within the last 5 years, capable of taking a six-minute walk test.

Age: 40+    Gender: Any Gender


Estimated Time Commitment

Several visits over the course of at least 52 weeks



Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Kris Eliopoulos
303.398.2622

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Galapagos


Request More Information

Due to concerns around COVID-19 and our focus on helping to meet this momentous challenge, we have temporarily paused enrollment for all trials requiring an in-person visit. Please feel free to request additional information about any of the trials we have posted and we will get back to you when enrollment resumes. For more resources and information on COVID-19 please visit our special coronavirus website at www.njhealth.org/coronavirus.


*
*
*
*